The conditions are favorable for another strong year of performance for CDMOs. In this podcast, we showcase an article written by Jim Miller, Consultant and Content Advisor at DCAT, that examines industry fundamentals and an outlook for pharma outsourcing in 2020. For the text version of this article go to dcatvci.org.
Key topics: (see Chapter Markers)
- Strong fundamentals but some risk
- Mergers and acquisitions: what may be ahead
- Big Pharma restructuring
- Upbeat outlook